Why It’s Time For TCR-based Therapies

TCR-Based Therapies

*Data acquired by Beacon Targeted Therapies

A record number of trials entered the clinic in 2019 with 15 trials forecast to finish in 2020 and many more to yield results. With an annual growth rate of 23.1%, this trend does not appear to be slowing, so this timely TCR-based therapy meeting is a unique opportunity to analyse and discuss progress as results emerge at a critical point in TCR development.

The large number of companies entering the TCR space is testament to progress in the field. With a combined effort to overcome HLA restrictions, there is a bright future for the delivery of TCR-based therapies to wider patient populations and cancer indications.

For more details about the program, speaker faculty or pricing and discounts, download the brochure.